Compare APWC & RLYB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | APWC | RLYB |
|---|---|---|
| Founded | 1996 | 2018 |
| Country | Taiwan | United States |
| Employees | N/A | 14 |
| Industry | Telecommunications Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 65.3M | 75.9M |
| IPO Year | 1997 | 2021 |
| Metric | APWC | RLYB |
|---|---|---|
| Price | $1.42 | $14.00 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 6.8K | ★ 289.2K |
| Earning Date | 04-29-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $858,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $12.60 | ★ N/A |
| Revenue Growth | N/A | ★ 43.00 |
| 52 Week Low | $1.27 | $0.27 |
| 52 Week High | $2.34 | $15.31 |
| Indicator | APWC | RLYB |
|---|---|---|
| Relative Strength Index (RSI) | 46.20 | 80.20 |
| Support Level | $1.28 | $0.54 |
| Resistance Level | $1.47 | $15.31 |
| Average True Range (ATR) | 0.06 | 0.71 |
| MACD | -0.01 | 0.23 |
| Stochastic Oscillator | 12.50 | 83.84 |
Asia Pacific Wire & Cable Corp Ltd is a holding company. It is principally engaged in the manufacture and distribution of enameled wire, power cable, and telecommunications products in Thailand, Singapore, Australia, PRC, Hong Kong and certain other markets in the Asia Pacific region. It also provides project engineering services in the supply, delivery and installation of power cables (SDI). Some of the company's products are Bare wires, Power cables, Communication cables, Electronic wires & cables, and Enamelled wires. The company's geographical segments are North Asia, Thailand, and Rest of the World.
Rallybio Corp is a clinical-stage biotechnology company comprised of experienced biopharma industry leaders with extensive research, development, and rare disease expertise with a mission to develop and commercialize life-transforming therapies for patients with severe and rare diseases. The company's program, RLYB116, is a differentiated complement component 5 (C5) inhibitor with the potential to treat diseases of complement dysregulation. The Company manages its operations as a single segment for the purposes of allocating resources, assessing performance, and making operating decisions. Rallybio's pipeline also includes RLYB332, a preclinical long-acting matriptase-2 antibody for the treatment of diseases of iron overload.